BioinvestGPT

BioinvestGPT ApS · Research use only

NCT05225415 (CT1812 in Dementia With Lewy Bodies): BVCT ex-ante prediction vs. reported outcome

On 15 May 2024, BioinvestGPT's BVCT predicted technical partial success and commercial failure for this trial. The 18 Dec 2024 readout is classified on the dashboard as True Negative (TN), a correct prediction. Recorded clinical-benefit conclusion: statistically significant (safety) and commercially probably insufficient (efficacy).

Clinical Trial

NCTID
NCT05225415
Acronym
COG1201
Drug Name
CT1812
Drug MoA
allosteric sigma-2 receptor antagonist
Drug Modality
small molecule
Drug Class
First-In-Class
Therapeutic Area
Nervous System Diseases
Indication
Dementia With Lewy Bodies
Human Patients
130
Sponsor
Cognition Therapeutics
Phase
Phase 2

Prediction of , index 1619

Prospective Prediction
Prediction Index
1619
Prediction Date
Commercial Prediction
FAILURE (commercially insufficient clinical benefit)
Technical Prediction
partial SUCCESS (statistically maybe significant yet very weak clinical benefit despite tolerable toxicity)

Readout of

Prediction Validation
Readout Date
Prediction To Readout
217 days in advance
Readout Data Interpretation
CT1812 met the safety primary endpoint with trends only of cognitive/functional improvements
Press Release
Prediction Result
Prediction Accuracy
Correct Prediction
Clinical Benefit Conclusion
statistically significant (safety) and commercially probably insufficient (efficacy)
Prediction Classification
True Negative (TN)

ClinicalTrials.gov record

ClinicalTrials.gov record, retrieved 2026-09-24. Third-party data.

Official title
A Randomized, Double-blind, Placebo-controlled, Phase 2, 6-month Study to Evaluate the Safety, Tolerability and Exploratory Efficacy of CT1812 in Subjects With Mild to Moderate Dementia With Lewy Bodies
Phase
Phase 2
Status
Completed
Enrollment
130
Lead sponsor
Cognition Therapeutics
Conditions
Dementia With Lewy Bodies
Interventions
DRUG: CT1812
Design
Randomized · Parallel · Quadruple
Primary purpose
Treatment
Start
2022-05-19
Primary completion
2024-11-25
Completion
2024-11-25
Results first posted
2026-03-12
Primary outcomes
  • Number of Study Participants With at Least One Mild, Moderate, or Severe Treatment Emergent Adverse Events (TEAEs) (Up to 210 Days)

NCT05225415 on ClinicalTrials.gov

Return to the dashboardClinicalTrials.gov

How to read these records: evidence · methodology · all trials